Magellan Rx Management earns reaccreditation from the National Committee for Quality Assurance

EAGAN, Minn. – Feb. 9, 2023 –  Magellan Rx Management, LLC (Magellan Rx), a Prime Therapeutics LLC  (Prime) company, today announced it was reaccredited by the National Committee for Quality Assurance (NCQA) for Utilization Management. NCQA Utilization Management Accreditation is a quality assessment program that focuses on consumer protection and customer service improvement.

“We are honored to receive this accreditation once again in utilization management from NCQA which reinforces our dedication and commitment to an evidence-based utilization management program designed to improve patient outcomes” said Tame Jaco, vice president of quality for Magellan Rx. “This achievement demonstrates our commitment to NCQA’s high quality standards as we continue to provide consistently high-quality medical management to our customers and members.”

NCQA Utilization Management Accreditation focuses on consumer protection and improvement in service to customers. Standards recognize that organizations that apply for accreditation have open access networks, and can improve service quality and utilize customized structures to meet purchaser needs. NCQA Utilization Management Accreditation reduces duplicative oversight and inefficient gathering of information by organizations.

“Achieving NCQA Utilization Management demonstrates that Magellan Rx has the systems, process and personnel in place to conduct utilization management in accordance with the strictest quality standards,” said NCQA President Margaret E. O’Kane.

NCQA has reviewed and accredited Magellan Rx Management’s Utilization Management functions only. For complete details on the scope of this review, visit www.ncqa.org.